The U.S. Food and Drug Administration’s accelerated approval program is meant to give patients early access to promising drugs. But how often do these drugs actually improve or extend patients’ lives?
In a new study, researchers found that most cancer drugs granted accelerated approval do not demonstrate such benefits within five years.
“Five years after the initial accelerated approval, you should have a definitive answer,” said Dr. Ezekiel Emanuel, a cancer specialist and bioethicist at the University of Pennsylvania who was not involved in the research. “Thousands of people are getting those drugs. That seems a mistake if we don’t know whether they work or not.”
The program was created in 1992 to speed access to HIV drugs. Today, 85% of accelerated approvals go to cancer drugs.
It allows the FDA to grant early approval to drugs that show promising initial results for treating debilitating or fatal diseases. In exchange, drug companies are expected to do rigorous testing and produce better evidence before gaining full approval.
Trump accepts a VP debate but wants it on Fox News. Harris has already said yes to CBS
Loperfido hits first MLB homer, Javier solid as Astros beat A's 8
Families of Mexican farmworker bus crash victims mourn the loss of their loved ones
Xavi reportedly under pressure at Barcelona after saying it will struggle to compete with Madrid
Dodgers acquire pitcher Yohan Ramírez from Mets for cash
Pride House on Seine River barge is inaugurated by Paris Olympics organizers
EU bans 4 more Russian media outlets from broadcasting in the bloc, citing disinformation
Hurricanes hold off Moana Pasifika to return to top spot in Super Rugby Pacific
Supreme Court declines to hear challenge to Maryland ban on rifles known as assault weapons
Israeli military finds bodies of 3 hostages in Gaza, including Shani Louk
‘The Blue Angels,’ filmed for IMAX, puts viewers in the ‘box’ with the elite flying squad
Jonathan Milan sprints to his 3rd stage win in the Giro d'Italia